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ABSTRACT
Introduction Ileus is a common and distressing condition 
characterised by gut dysfunction after surgery. While a 
number of interventions have aimed to curtail its impact 
on patients and healthcare systems, ileus is still an unmet 
challenge. Electrical stimulation of the vagus nerve is a 
promising new treatment due to its role in modulating the 
neuro- immune axis through a novel anti- inflammatory 
reflex. The protocol for a feasibility study of non- invasive 
vagus nerve stimulation (nVNS), and a programme of 
mechanistic and qualitative studies, is described.
Methods and analysis This is a participant- blinded, 
parallel- group, randomised, sham- controlled feasibility trial 
(IDEAL Stage 2b) of self- administered nVNS. One hundred 
forty patients planned for elective, minimally invasive, 
colorectal surgery will be randomised to four schedules 
of nVNS before and after surgery. Feasibility outcomes 
include assessments of recruitment and attrition, adequacy 
of blinding and compliance to the intervention. Clinical 
outcomes include bowel function and length of hospital 
stay. A series of mechanistic substudies exploring the 
impact of nVNS on inflammation and bowel motility 
will inform the design of the final stimulation schedule. 
Semistructured interviews with participants will explore 
experiences and perceptions of the intervention, while 
interviews with patients who decline participation will 
explore barriers to recruitment.
Ethics and dissemination The protocol has been 
approved by the Tyne and Wear South National Health 
Service (NHS) Research Ethics Committee (19/NE/0217) 
on 2 July 2019. Feasibility, mechanistic and qualitative 
findings will be disseminated to national and international 
partners through peer- reviewed publications, academic 
conferences, social media channels and stakeholder 
engagement activities. The findings will build a case for or 
against progression to a definitive randomised assessment 
as well as informing key elements of study design.
Trial registration number ISRCTN62033341.
INTRODUCTION
Ileus is a distressing condition that occurs 
in 10%–20% of patients undergoing major 
abdominal surgery.1 It is characterised by 
painful abdominal distension, persistent 
vomiting and delayed bowel function. This 
usually resolves 2–4 days after surgery, but 
in some cases, it may persist in excess of 10 
days.2 The impact of ileus is extensive. For 
patients, it increases the length of hospital 
stay and increases the risk of serious postop-
erative complications such as pneumonia, 
surgical site infection and venous thrombo-
embolic events.3 For hospitals, it is econom-
ically burdensome and is associated with an 
increase of 71% in healthcare costs.4 Once 
considered to be a normal consequence of 
surgical recovery, the Association of Colo-
proctology of Great Britain and Ireland now 
considers ileus to be a research priority.5
In the last 20 years, a number of inter-
ventions to prevent ileus and its clinical 
sequelae have been explored.6 Strategies to 
encourage early or sham feeding (chewing 
gum) have been studied extensively, but 
evidence for their effectiveness remains 
contentious.7 8 New approaches to periop-
erative management (such as intravenous 
lidocaine) have been explored, but uncer-
tainty relating to efficacy, dose and timing 
persists.9 Novel drugs such as mu- opioid 
receptor antagonists have shown promising 
results, but economic and regulatory barriers 
Strengths and limitations of this study
 ► Feasibility outcomes will support the development 
of a definitive, randomised controlled trial, including 
considerations of recruitment, device compliance 
and sham blinding.
 ► Qualitative outcomes will explore possible barri-
ers to participation and compliance with the self- 
administered device before and after colorectal 
surgery.
 ► The study will not explore the most appropriate 
outcome to be used in a definitive randomised con-
trolled trial, but other related work done in parallel 
will fill this need.
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have limited their uptake beyond North America. The 
consensus of existing literature suggests that minimally 
invasive surgery and protocol- driven recovery offer the 
best chances of preventing ileus.10 Uncertainty exists over 
the pathophysiology of ileus, however, which is problem-
atic for designing clinical interventions that are justified 
by strong scientific evidence.
Stimulation of the vagus nerve may represent a novel 
and evidence- based approach to reduce ileus after surgery. 
In preclinical models, electrical stimulation of the vagus 
nerve accelerates the recovery of gastrointestinal transit. 
This is facilitated through vagal afferents targeting the 
hypothalamic–pituitary–adrenal axis and vagal efferents 
targeting the cholinergic anti- inflammatory pathway, 
which attenuate inflammatory- mediated gut dysfunc-
tion.11–13 Early clinical studies have suggested that this is 
directly translatable to humans undergoing surgery.14 15 
Challenges exist, however, as to how vagus nerve stimula-
tion can be done safely, how its efficacy can be optimised 
and how patient acceptability can be ensured. A protocol 
for a randomised feasibility trial of non- invasive vagus 
nerve stimulation (nVNS) to reduce ileus, as well as a 
series of mechanistic and qualitative studies, is described.
METHODS
Ethics & governance
Ethical approval for the study was obtained from North 
East—Tyne and Wear South Research Ethics Committee 
(19/NE/0217) on 2 July 2019. The study was prospec-
tively registered on the ISRCTN registry (http://www. 
isrctn. com/ ISRCTN62033341) on 11 October 2019 
prior to the start of recruitment (online supplemental 
file 1). The study devices will be provided through the 
manufacturer’s (electroCore) Investigator Initiated 
Trial Programme. The present manuscript is reported 
according to the Standard Protocol Items: Recommen-
dations For Interventional Trials 2013 Checklist (online 
supplemental file 2).16
Aims and objectives
The aim of this study is to determine the feasibility 
of performing a multicentre, phase III randomised 
controlled trial (RCT) of nVNS to reduce ileus after 
colorectal surgery. The following objectives will explore 
the case for progression to a phase III trial:
 ► To estimate the proportion of patients screened who 
are eligible for approach.
 ► To estimate the number of approached patients who 
consent to randomisation.
 ► To assess the adequacy of participant blinding to the 
allocated intervention.
 ► To assess participant compliance to the intervention 
schedule.
 ► To explore the safety of the intervention schedule.
 ► To estimate the rate of missing outcome data, rate of 
withdrawal and loss to follow- up.
Study design
This study is a participant- blinded, parallel- group, 
randomised, sham- controlled feasibility trial (IDEAL 
Stage 2b) of nVNS to reduce ileus after colorectal 
surgery (figure 1). One hundred and forty participants 
will be recruited across two study sites. Participants will 
be randomised to four arms (1:1:1:1) according to the 
following stimulation schedules:
 ► Preoperative stimulation and postoperative 
stimulation.
Figure 1 Study flow chart.
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 ► Preoperative sham and postoperative stimulation.
 ► Preoperative stimulation and postoperative sham.
 ► Preoperative sham and postoperative sham.
The estimated trial duration is 24 months, and all 
participants will be followed up for 30 days after the date 
of surgery.
Study setting
The intervention will take place within the community 
(preoperative stimulation) and in hospital (postopera-
tive stimulation). All participants will undergo surgery at 
one of two large teaching hospitals (St James’s Univer-
sity Hospital, Leeds, and Bradford Royal Infirmary, Brad-
ford). Both provide elective colorectal cancer services 
including laparoscopic surgery within a programme of 
enhanced recovery.
Eligibility criteria
To be considered eligible for the trial, patients must satisfy 
all of the following inclusion criteria:
 ► Aged ≥18 years.
 ► Able to provide written informed consent.
 ► Planned to undergo elective, minimally invasive 
(laparoscopic or robotic) surgery with a planned 
anastomosis/no routine plans for a diverting stoma, 
including one of the procedures listed in table 1.
Presence of any of the following exclusion criteria will 
preclude participation in the trial:
 ► Severe cardiac disease (myocardial infarction in the 
last 12 months, heart failure with New York Heart Asso-
ciation Scale ≥3, second- degree or third- degree atrio-
ventricular block, permanent atrial fibrillation/flutter 
or previous ventricular tachycardia/fibrillation).
 ► Seizures or recurrent episodes of syncope (>1) in the 
last 5 years.
 ► Previous transient ischaemic attack or cerebral 
vascular accident.
 ► Previous vagotomy at any anatomical location.
 ► Confirmed diagnosis of chronic gastrointestinal 
inflammatory condition.
 ► Confirmed diagnosis of neuroendocrine tumour.
 ► Existing gastrointestinal stoma.
 ► Implanted electrical stimulator device (such as cardiac 
pacemaker or defibrillator).
 ► Structural abnormality of the neck anatomy that may 
impact on use of the device.
 ► Belonging to a vulnerable population (such as those 
lacking capacity and prisoners).
 ► Pregnant, nursing or thinking of becoming pregnant 
during the study period.
Participants will not be eligible for entry into other inter-
ventional studies that aim to optimise surgical recovery or 
for which the intervention may impact on bowel function.
Intervention
nVNS will be self- administered by participants using 
the gammaCore device (electroCore, New Jersey, USA). 
This provides a transcutaneous electrical stimulation 
comprising of 5×5 KHz sine wave complexes delivered 
over 1 ms and repeated at 25 Hz (maximum voltage: 24 
V; maximum output current: 60 mA). The surface land-
mark of the carotid pulse is used to guide positioning of 
the device over the cervical vagus nerve. Participants will 
self- administer the device twice daily for 5 days before and 
after surgery, with each administration lasting for 2 min 
on either side of the neck. Participants will be instructed 
to adjust the stimulation setting to the maximum toler-
ated level. A sham device identical in appearance will be 
used as a control. This produces a subtherapeutic stimu-
lation (0.1 Hz biphasic direct current) while providing a 
perceptible stimulation sensation.
Study outcome measures
The following outcomes will assess the feasibility of a 
phase III RCT of nVNS to reduce ileus:
 ► Proportion of eligible patients identified from 
screening logs.
 ► Number of eligible patients randomised (per month) 
and reasons for approach failure.
 ► Adequacy of participant blinding according to a 
blinding poll (Bang Blinding Index).17
 ► Compliance to the preoperative and postopera-
tive stimulation schedules according to participant- 
reported diaries (maximum of 10 stimulations before 
and after surgery).
 ► Incidence of complications and serious complications 
within 30 days.
 ► Proportion of missing clinical outcome data, with-
drawals and loss to follow- up.
Progression will be determined using the parameters 
outlined in table 2. ‘Progress’ outcomes will build a case 
for progression to a phase III trial. ‘Adjust’ outcomes will 
build a case for progression after appropriate amend-
ments have been made. ‘Stop’ outcomes will contrain-
dicate a case for progression, unless modifiable barriers 
are identified and further assessments of feasibility are 
undertaken. The predominance of such outcomes will be 
considered by the research team in the decision- making 
process.
Clinical data will be collected to explore variability in 
candidate measures including number of postoperative 
days to first flatus, first stool, first oral intake, hospital 
Table 1 Eligible procedures
Right- sided resection Left- sided resection
Ileocolic/caecal resection Extended left hemicolectomy








Other segmental colonic 
resection
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discharge and GI-2 (composite outcome of passage of 
stool and oral tolerance).18
Participant timeline
The timing of study procedures, clinical assessments 
and collection points are summarised in table 3. Partic-
ipants will attend a preintervention study visit, where a 
trained investigator will provide an interactive tutorial on 
how to self- administer the device. This will provide an 
opportunity to practice self- administration under direct 
supervision. Allocation of study devices will take place 
at two timepoints. The first will take place at the pre- 
intervention study visit, where devices will be provided 
for use in the community. On admission to hospital, 
these will be collected and switched with the postop-
erative device. Throughout the stimulation schedule, 
participants will record their compliance to the device 
schedule using stimulation diaries. Gastrointestinal 
function will be recorded daily, as reported by patients. 
On the last stimulation day, participants will complete a 
poll to explore the performance of blinding before and 
after surgery. Follow- up data (including the occurrence 
of complications and serious complications) will be 
collected 30 days after surgery to capture events, which 
may occur during the index hospital admission or after 
discharge.
Sample size
As a feasibility study, no formal power calculation has 
been performed. In this four- arm parallel- group design, 
35 participants per arm will allow robust estimates of vari-
ability in continuous clinical outcomes, and 70 patients 
randomised to pre- surgery and post- surgery groups will 
allow robust estimates of recruitment parameters.19 The 
total sample size of 140 allows robust exploration of both 
clinical and recruitment- related objectives.
Recruitment
Participants will be approached with written information 
in the outpatient departments of St James’s University 
Hospital and Bradford Royal Infirmary. Research staff 
will be available to discuss the study over the phone, as 
well as opportunities to meet in person during patients’ 
routine schedule of pre- assessment and anaesthetic 
review appointments. Consent for participation in the 
study will be gathered using the approved consent form 
(online supplemental file 3).
Randomisation and allocation
Following confirmation of written informed consent, 
participants will be randomised to one of four interven-
tion arms. The randomisation list will be prepared by 
an independent statistician using block randomisation 
with a variable block size. This will be stratified for type 
of colorectal resection (right- sided and left- sided) and 
recruitment centre. Randomisation will be facilitated 
centrally using an online 24- hour service and will be 
performed by study investigators.
Blinding
Participants will be blinded to the study intervention 
before and after surgery. This is made possible through 
the use of a sham stimulator device, which is identical in 
appearance, weight and user interface, as well as being 
designed to provide a perceptible sub- therapeutic 
stimulation. All devices will be switched irrespective of 
whether the type of device (active or sham) remains 
constant throughout the pre- operative and post- 
operative schedules. Investigators and clinical outcome 
assessors will be unblinded to the intervention. Since 
outcomes relating to gastrointestinal function are 
patient- reported, the risk of assessor bias is considered 
to be low.
Table 2 Progression criteria
Criteria Stop Adjust Progress
Proportion of eligible patients identified from screening logs <10% 10%–20% >20%
Number of eligible patients randomised over 24 months (site: 
SJUH)
≤2 per month 3–4 per month ≥5 per month
Number of eligible patients randomised over 18 months (site: BRI) <1 per month 1–2 per month ≥3 per month




Index −0.2 to −0.5
Or index 0.2–0.5
Index 0 to −0.19
Or index 0–0.19









Proportion of missing clinical outcome data >40% 15%–30% <15%
Proportion of randomised patients lost to follow- up >40% 15%–30% <15%




<5% increase in 
complications
BRI, Bradford Royal Infirmary; SJUH, St James’s University Hospital.
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Data collection and management
All trial data will be prospectively entered onto case 
report forms by dedicated research staff (a clinical 
research fellow and research nurses). Physical data will be 
stored in a restricted- access research unit, accessible only 
to the research team. All electronic data will be stored 
in pseudo- anonymised format at the University of Leeds 
according to sponsor requirements. As a feasibility study, 
a data monitoring committee is not planned.
Statistical analysis plan
All analyses will follow a pre- determined statistical anal-
ysis plan20 and will be overseen by a qualified medical 
statistician. Recruitment, baseline characteristics, compli-
ance and outcome data will be presented descriptively 
as rates (categorical) and means (continuous) with 
95% CIs. No formal statistical hypothesis testing across 
randomised groups will be conducted. Groups may be 
collapsed to pre- surgery and post- surgery stimulus versus 
sham and reported descriptively. Blinding will be anal-
ysed according to the Bang Blinding Index, with an index 
of >0.2 representing unblinding, −0.2 to 0.2 representing 
random guesses and <−0.2 representing opposite guessing 
(also considered a source of unblinding).17 All analyses 
will be performed for intention- to- treat (treatment as 
randomised) and per- protocol populations. Possible 
reasons for exclusion from the per- protocol population 
include non- compliance to the device schedule (defined 
as any deviation from the 5- day preoperative and postop-
erative stimulation schedule), conversion from laparo-
scopic to open surgery, formation of unplanned stoma, 
return to theatre prior to the return of bowel function 
and randomisation errors. The trial will be reported 
according to the Consolidated Standards of Reporting 
Trials Checklist.21
Patient and public involvement
As a self- administered device, patient and public involve-
ment is essential at each stage of the study. The design 
of this feasibility trial was informed through a patient 
focus group in collaboration with a study- specific patient 
representative. A patient advisory group comprising of 
4–6 patients with experience of the intervention will be 
convened on six occasions across 3 years (including 1 year 
prior to study recruitment and 2 years during recruit-
ment). The programme of discussion will be determined 
by the group but will include issues of patient approach, 
intervention burden, device training and design of study 
materials.
Dissemination
Feasibility, mechanistic and qualitative findings will be 
disseminated to professional and patient groups via 
peer- reviewed publications, academic conferences, social 
media channels and stakeholder engagement activities.
Trial substudies
Participants will be invited to take part in the following 
optional substudies.
Inflammatory response substudy
The inflammatory response substudy will explore the 
effect of nVNS on measures of systemic and peritoneal 
inflammation. This will explore differences in efficacy 
between randomised arms, which will assist with the 
design of the final intervention. Recruitment to this 
substudy will take place at the lead site only (St James’s 
University Hospital). Additional eligibility criteria will 
apply, as outlined in box 1. Venous blood draws will be 
performed at baseline, 2 hours, 24 hours and 48 hours 
after the start of surgery. Peritoneal lavage fluid will also 
be collected at the start and end of surgery. Lavages will 
be performed by instilling 20 mL of sterile 0.9% sodium 
chloride onto the small bowel using a Foley catheter and 
bladder tip syringe, followed by collection of 5–10 mL of 
fluid after 30 s, as described previously.22 Serum (systemic) 
and fluid (peritoneal) levels of tumour necrosis factor 
alpha, interleukin (IL) 1 beta and IL-6 will be analysed 
using ELISA.23 24
Bowel motility substudy
The motility substudy will explore the effect of nVNS 
on global small bowel motility. Differences in efficacy 
between randomised groups will inform the design of 
the final intervention. Recruitment will take place at the 
lead site only. Additional eligibility criteria (box 1) will 
apply with a recruitment target of 10 participants per 
group (total sample: 40 participants). Magnetic reso-
nance enterography will be performed at baseline and on 
the third postoperative day in the supine position under 
breath hold conditions while a series of motility acquisi-
tions are performed. Oral preparation with a single glass 
of water will take place 30 min prior to the scan. These will 
be registered with dedicated software and a quantitative 
motility score generated to depict bowel wall motion.25
Qualitative substudy
A qualitative substudy will explore participants’ accept-
ability of the trial recruitment process, intervention, their 
experiences of self- administration and any challenges 
with device blinding. Recruitment will take place at the 
lead site with a target sample of five participants per group 
Box 1 Substudy additional exclusion criteria
Inflammatory response substudy
 ► Regular use of non- steroidal anti- inflammatory drugs in the pre-
ceding 7 days.
 ► Medical condition requiring oral or injectable steroids.
 ► Neoadjuvant chemoradiotherapy within 12 months prior to surgery.
Bowel motility substudy
 ► Indwelling pacemaker or cardiac defibrillator device.
 ► Non- magnetic resonance compatible metallic implants, prostheses, 
neurosurgical clips, indwelling stimulator or pump devices, which 
would preclude safe MRI.
 ► Claustrophobia.
 ► Metallic foreign bodies in the eyes.
7Chapman SJ, et al. BMJ Open 2021;11:e046313. doi:10.1136/bmjopen-2020-046313
Open access
(total sample: 20 participants). In addition, five patients 
who declined participation in the study will be recruited 
to explore barriers to study enrolment. A maximum vari-
ation approach to sampling will be used to ensure that 
a wide variety of perspectives are captured (accounting 
for age, sex, indication for surgery, and device compli-
ance). Semi- structured interviews will be conducted 
after hospital discharge in hospital or in the community. 
Questions will be informed by a topic guide and will be 
recorded in preparation for transcription. A thematic 
framework approach will be used for analysis, comprising 
five key stages: (1) familiarisation with data, (2) identi-
fying the thematic framework, (3) indexing, (4) charting 
and (5) mapping and interpreting.26 The thematic anal-
ysis will be modified in light of new data, and a process 
of constant comparison will be used to examine across 
themes and cases. Qualitative data will be managed in 
NVivo V.11 (Melbourne, Australia).
DISCUSSION
Although ileus is a common problem after surgery, 
limited progress has been made to curtail its impact on 
patients and healthcare systems in the last 20 years.6 The 
most successful measures have been the widespread intro-
duction of minimally invasive surgery and the develop-
ment of evidence- based enhanced recovery protocols. 
These gains are likely facilitated through reductions in 
inflammatory- induced and opioid- induced intestinal 
smooth muscle dysfunction, leading to faster recovery of 
bowel function.27 28 The use of vagus nerve stimulation 
to reduce ileus is a new concept, which draws on similar 
principles. Its efficacy has been demonstrated consistently 
in pre- clinical studies through activation of a cholinergic 
anti- inflammatory pathway, leading to a faster restoration 
of intestinal transit.11 In keeping with this, intraoperative 
stimulation of the vagus nerve in humans has been shown 
to attenuate systemic markers of inflammation after major 
abdominal surgery.14 Taken together, this suggests that 
the anti- inflammatory mechanism of vagus nerve stimula-
tion is directly translatable to patients and may represent 
a novel approach to reduce ileus after surgery.
Most previous studies of vagus nerve stimulation have 
involved surgical access to the neck or abdomen. This is 
challenging for clinical translation because the procedure 
is invasive and technically demanding. Non- invasive stim-
ulation over the cervical surface landmark aims to miti-
gate these challenges and presents a number of possible 
advantages. One of these is the opportunity for stimu-
lation before and after surgery. This is attractive since 
some evidence suggests that activation of the cholinergic 
anti- inflammatory pathway (using prucalopride) is most 
effective when done pre- operatively.29 Another is the 
opportunity for stimulation on multiple occasions rather 
than a single intra- operative episode, which expands the 
scope for intervention. In this study, a schedule of 5 days 
will be used as this represents the time during which most 
patients are expected to regain bowel function.2 Finally, 
stimulation can be self- administered by patients, which 
encourages active participation. Previous evidence has 
shown that active participation is a key motivator during 
recovery after surgery.30
In contrast, there are several possible challenges associ-
ated with studying and implementing nVNS in this setting. 
First, patient self- administration requires adequate skill, 
understanding and compliance, which may be difficult 
in the post- operative setting. A dedicated programme of 
training, including device positioning, aims to mitigate 
this. Second, the non- invasive approach to stimulation is 
less precise than conventional stimulation since contact 
with the vagus nerve cannot be confirmed objectively. 
This is mitigated through the use of a standard technique 
(stimulation over the cervical surface landmark), which 
has been shown to increase heart rate variability, reduce 
markers of systemic inflammation and generate vagal 
somatosensory evoked potentials (indicators of vagal 
stimulation) previously in healthy volunteers.31–34 Finally, 
identifying an adequate sham intervention by which to 
compare nVNS is challenging. In previous healthy volun-
teer studies, nVNS has been shown to significantly reduce 
the expression of inflammatory cytokines from baseline 
but not when using the sham device.32 It is possible that 
manual instrumentation of the device may be sufficient 
to elicit some vagal activity, but this is considered minimal 
and is comparable across both device types. Providing that 
these challenges can be addressed, nVNS may provide a 
practical approach to stimulating the vagus nerve in the 
pre- operative and post- operative setting.
The present study will inform the feasibility of a phase III 
RCT of nVNS by addressing key challenges in trial design. 
This includes compliance to the stimulation schedule in a 
complex clinical setting where unique barriers may exist. 
It also includes the adequacy of participant blinding. This 
is important in studies of electrical nerve stimulation 
where sham controls may be associated with statistical 
improvements in clinical outcomes.35 Some issues of feasi-
bility are beyond the scope of this study. The selection 
of outcomes for ileus is poorly standardised, with over 50 
different outcomes identified from previous literature in 
the last 20 years.36 To address this, a core outcome set 
for gastrointestinal recovery is under development by an 
international collaboration of clinicians and patients.37 
This will help to standardise reporting in the future. 
In addition, the feasibility of implementing nVNS into 
enhanced recovery after surgery protocols across diverse 
settings will remain unclear. The present study explores 
the feasibility of nVNS in two large teaching hospitals, but 
further consideration of barriers to implementation will 
be required.
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